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Gemfibrozil Reduces Plasma C-Reactive
Protein Levels in Abdominally Obese Men
With the Atherogenic Dyslipidemia of the
Metabolic Syndrome
To the Editor:
Recent data from Veterans Affairs High-Density Lipoprotein
Cholesterol Intervention Trial (VA-HIT) have recently reported that
pharmacological treatment with a fibrate (gemfibrozil) significantly
reduced coronary heart disease (CHD) risk among men with a history
of CHD who had low HDL-cholesterol and LDL-cholesterol levels at
baseline evaluation.1 Moreover, this study also demonstrated that
changes in the lipoprotein-lipid profile only partially explained the
beneficial effect of gemfibrozil on CHD risk, suggesting that other
factors may be responsible for the reduction in the risk of CHD
observed among patients undergoing fibrate therapy.2
On the other hand, the contribution of inflammation to the develop-
ment of atherosclerosis and CHD is increasingly recognized, and recent
studies have identified some inflammatory markers, such as plasma
C-reactive protein (CRP) and cytokines, as CHD risk factors.3,4 Recent
data have suggested that statins and fibrates may favorably decrease
markers of inflammation.5–8
However, the effect of fibrates among abdominally obese men with
the atherogenic dyslipidemia of the metabolic syndrome (a condition
associated with markedly elevated inflammatory markers) has, to the
best of our knowledge, never been reported. Thus, the aim of the present
study was to examine the effect of a 6-month fibrate treatment on
plasma CRP concentrations and cytokine levels such as interleukin
(IL)-6 and tumor necrosis factor (TNF)- in a sample of abdominally
obese men with the atherogenic dyslipidemia of the metabolic
syndrome.
Abdominally obese subjects (n31 per treatment group) of the
present study were asymptomatic volunteers who were between 25 and
55 years of age with a body mass index (BMI) between 27 and 40 kg/m2
and a waist-to-hip ratio 0.95, as previously described.9 Subjects
received placebo or gemfibrozil (600 mg twice a day) for a period of 6
months. The study was approved by the Medical Ethics Committee of
Laval University. Anthropometric as well as laboratory measurements
were performed by using standardized techniques, as previously de-
scribed.9 Measurement of CRP levels was obtained with a highly
sensitive immunoassay which used a monoclonal antibody coated to
polystyrene particles (hs-CRP) performed on the Behring BN-100
nephelometer (Dade Behring). Cytokine levels were measured with an
immunoassay by using monoclonal antibodies specific for human
TNF- and IL-6.
Both treatment groups showed small but statistically significant
reductions in weight, BMI, waist circumference, and visceral adipose
tissue accumulation (P0.05). Although decreases in total cholesterol
and apolipoprotein B concentrations were significant for both groups
after the 6-month period, the magnitude of changes was greater in the
gemfibrozil group as compared with placebo (P0.03). Moreover,
significant changes in triglyceride (1.080.89 mmol/L, P0.0001;
36.8%) and HDL-cholesterol (0.080.10 mmol/L, P0.0001;
9.48%) levels as well as in the cholesterol/HDL-cholesterol ratio
(1.121.19, P0.0001; 16.5%) were observed with only gemfi-
brozil treatment (P0.0001).
The effects of 6-month placebo or gemfibrozil treatment on
plasma CRP and TNF- or IL-6 levels are shown in the Figure.
Plasma CRP concentrations were significantly reduced by only
gemfibrozil therapy (32.7%) (2.581.99 vs 1.461.19 g/mL,
P0.003 for baseline and follow-up values, respectively). Fur-
thermore, the change in the gemfibrozil group was significantly
greater than in the placebo arm (P0.01). However, neither
TNF- nor IL-6 levels were significantly reduced by gemfibrozil
therapy.
Atherosclerosis is recognized to have an inflammatory component. In
that sense, plasma CRP levels have been found to be predictive of
cardiac events,10 to be associated with elevated BMI and with a high
abdominal fat accumulation10,11 as well as to be related to the high
triglyceride–low HDL-cholesterol dyslipidemia.10 Finally, plasma CRP
has been reported to be significantly reduced by hypolipidemic
drugs.5,7,8,12
In this regard, studies have reported the beneficial effects of statin
therapy on CRP levels.5,12 Fibrates have also been shown not only to
improve the high triglyceride–low HDL-cholesterol dyslipidemic
state1,9,13 but also to reduce CHD risk1 and decrease plasma CRP
levels.7,8 In the present study, gemfibrozil treatment produced signifi-
cant reductions in CRP levels. To the best of our knowledge, it is the
first study to demonstrate that gemfibrozil therapy can favorably alter
CRP concentrations among abdominally obese dyslipidemic patients
with the features of the metabolic syndrome.
Circulating levels of TNF- and IL-6 have been shown to stimulate
the production of CRP.14 Accordingly, it has been demonstrated that
bezafibrate therapy reduced the production capacity of these two
cytokines as well as CRP concentrations.8 However, in the present
study, gemfibrozil did not appear to affect the production of these
cytokines, suggesting that this drug may rather alter the effect of IL-6
and TNF- on CRP production. There are discrepancies in the literature
regarding the impact of fibrates on CRP and cytokine levels and the type
of patients as well as duration of trials may partly contribute to explain
such differences.
In vitro studies have shown that fibrates have pleiotropic effects
including the reduction of the inflammation process at the level of the
vascular wall.15 Fibric acids such as gemfibrozil are PPAR ligands that
Effect of a 6-month gemfibrozil treatment
on plasma CRP, TNF-, or IL-6 levels in a
sample of abdominally obese men with the
atherogenic dyslipidemia of the metabolic
syndrome.
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inhibit the progressive formation of atherosclerosis lesions,15 which also
involves the inflammatory component.16 Thus, fibrates may reduce/slow
atherosclerosis development not only through their hypolipidemic prop-
erties but also by decreasing the inflammation of the vascular wall.17
In summary, these results suggest that the beneficial effect of
gemfibrozil on plasma CRP levels could represent another mechanism
by which fibric acids may favorably reduce CHD risk by improving the
low chronic inflammation state of abdominally obese dyslipidemic
patients with the atherogenic dyslipidemia of the metabolic syndrome.
Moreover, this positive effect was not mediated by changes in the
concentrations of some inflammatory cytokines potentially regulating
the production of CRP. Whether this effect of gemfibrozil on CRP plays
a role in explaining the favorable impact of this fibric acid on CHD
events among low HDL-cholesterol patients with type 2 diabetes or the
metabolic syndrome18 will require further studies.
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IgG Is Higher in South Asians Than
Europeans: Does Infection Contribute to
Ethnic Variation In Cardiovascular Disease?
To the Editor:
Coronary heart disease (CHD) mortality is 40% higher in UK
residents born in the Indian subcontinent than in the general UK
population, a difference not explained by traditional cardiovascular risk
factors. The burden of chronic infections has been associated with
increased risk of CHD,1 and South Asians are likely to have a different
lifetime exposure to infection than those of European origin. Serum
gamma globulin (IgG) is a nonspecific measure of immune activation.
Elevated levels have been associated with increased risk of myocardial
infarction.2
We measured total IgG using quantitative enzyme linked immunosor-
bent assays (ELISA)3 in stored sera from 302 European and 302 South
Asian participants in the Newcastle Heart Project, a stratified population
sample of men and women 25 to 74 years old in Newcastle on Tyne,
UK.4 The study was approved by the local ethics committee, and
participants gave written informed consent. In a previous study, we
measured C-reactive protein (CRP) using a highly sensitive method in a
subsample of 100 South Asian participants.5 Of those included in the
present study, 35 also had measurements available for CRP. IgG was log
transformed, and results are presented as geometric means.
The mean age (SD) of Europeans was 54.5 years (13.1) and of South
Asians 50.1 (12.1). Geometric mean IgG (95% confidence interval [CI])
was 7.4 (6.7, 8.2) g/L among Europeans and 13.5 (12.1, 15.2) g/L
among all South Asians: 13.9 (11.4, 17.0) among Indians, 14.0 (11.8,
16.5) among Pakistanis, and 11.9 (9.2, 15.3) among Bangladeshis.
Although levels were lowest among current smokers, IgG was higher in
South Asians than in Europeans in each smoking category and in Indian,
Pakistani, and Bangladeshi groups (Table). Adjusted for age, sex, and
smoking status, geometric mean IgG was 75% higher (95% CI 48, 108)
in South Asians.
Among 35 South Asian subjects (17 female) with information about
CRP levels, there was a correlation (r0.48, P0.003) between log
CRP and log total IgG.
Higher levels of total IgG have been reported in US blacks compared
with whites,6 although the difference (30%) was much smaller than the
one we report here. This and the findings we report are both consistent
with the hypothesis that people with ancestral origins in tropical
environments have experienced genetic selection for increased pro-
inflammatory responses.7 The association between IgG and CRP in the
small number of subjects with both measures available links raised IgG
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in this population to an established marker of CHD risk. We have also
previously reported raised levels of leukocytes in Bangladeshis com-
pared with Europeans.4
We found substantially higher levels of IgG in South Asians com-
pared with Europeans, a difference not explained by factors known to be
associated with IgG levels. This may reflect genetic differences, differ-
ent exposures to infection, or ethnic differences in inflammatory
processes. This finding is consistent with and could lend support to the
hypothesis that the cumulative burden of infection is relevant to the
excess of CHD in UK South Asians and requires confirmation from
further studies.
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Geometric Mean (95% CI) Total IgG (g/L) and Number
European Whites South Asians* Indians Pakistanis Bangladeshis
Mean (CI) No. Mean (CI) No. Mean (CI) No. Mean (CI) No. Mean (CI) No.
Men
All 7.2 (6.3,8.2) 141 12.4 (10.5,14.6) 134 12.0 ( 8.8,16.4) 44 14.1 (11.2,17.7) 62 9.6 (6.4,14.4) 28
Nonsmokers 9.5 (6.9,13.1) 32 12.8 (9.9,16.6) 58 13.6 (8.8,20.9) 29 11.8 (8.4,16.6) 26 14.3 (0.9,238.2) 3
Exsmokers 7.0 (5.8,8.3) 67 13.6 (8.9,20.7) 26 7.3 (1.6,33.1) 5 17.4 (10.6,28.5) 17 10.4 (1.9,55.4) 4
Current smokers 6.2 (4.7,8.0) 41 11.1 (8.3,14.7) 46 10.7 (6.8,16.7) 8 14.5 (9.1,23.2) 18 8.8 (5.3,14.5) 20
Women
All 7.6 (6.6,8.7) 153 14.6 (12.5,17.1) 163 15.2 (11.8,19.8) 72 13.8 (10.8,17.7) 66 15.0 (11.0,20.5) 25
Nonsmokers 7.8 (6.4,9.5) 61 14.7 (12.6,17.3) 151 15.2 (11.8,19.8) 72 14.5 (11.3,18.6) 59 13.7 (10.0,18.8) 20
Exsmokers 7.9 (6.0,10.4) 47    0    0    0    0
Current smokers 6.9 (5.3,9.1) 44 11.3 (1.0,132.3) 3    0 11.3 (1.0,132.3) 3    0
Men and women† 7.6 (6.8,8.4) 300 13.2 (11.8,14.8) 289 13.3 (11.1,15.9) 117 14.0 (11.8,16.5) 124 11.5 (8.8,15.0) 48
Totals in each smoking category do not sum to the total for each sex because of cases with missing information about smoking.
*Totals for Indians, Pakistanis, and Bangladeshis are included in the total for South Asians.
†Adjusted for age, sex, and smoking status using linear regression.
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